Bellevue Group Ag Relmada Therapeutics, Inc. Transaction History

Bellevue Group Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $332,822 - $673,282	18,187 Added 51.96%	53,187 $1.97 Million
Q2 2022 Aug 11, 2022	BUY	$16.5 - $30.34 $313,500 - $576,460	19,000 Added 118.75%	35,000 $665,000
Q1 2022 May 13, 2022	BUY	$16.72 - $26.99 $267,520 - $431,840	16,000 New	16,000 $432,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.7M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.